Acumen Pharmaceuticals, Inc. (ABOS)
NASDAQ: ABOS · Real-Time Price · USD
1.850
+0.050 (2.78%)
At close: Dec 20, 2024, 4:00 PM
1.890
+0.040 (2.16%)
After-hours: Dec 20, 2024, 4:27 PM EST
Acumen Pharmaceuticals Stock Forecast
Stock Price Forecast
The 3 analysts with 12-month price forecasts for ABOS stock have an average target of 9.33, with a low estimate of 6.00 and a high estimate of 15. The average target predicts an increase of 404.32% from the current stock price of 1.85.
Analyst Consensus: Strong Buy
* Price targets were last updated on Nov 13, 2024.
Analyst Ratings
The average analyst rating for ABOS stock from 3 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
Rating | Jul '24 | Aug '24 | Sep '24 | Oct '24 | Nov '24 | Dec '24 |
---|---|---|---|---|---|---|
Strong Buy | 4 | 4 | 4 | 4 | 4 | 3 |
Buy | 1 | 0 | 0 | 0 | 0 | 0 |
Hold | 0 | 0 | 0 | 0 | 0 | 0 |
Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Total | 5 | 4 | 4 | 4 | 4 | 3 |
Latest Forecasts
Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
---|---|---|---|---|---|---|---|
HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $15 | Strong Buy | Reiterates | $15 | +710.81% | Nov 13, 2024 |
HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $15 | Strong Buy | Reiterates | $15 | +710.81% | Oct 3, 2024 |
UBS | UBS | Strong Buy Maintains $14 → $6 | Strong Buy | Maintains | $14 → $6 | +224.32% | Aug 15, 2024 |
HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $15 | Strong Buy | Reiterates | $15 | +710.81% | Aug 14, 2024 |
Citigroup | Citigroup | Strong Buy Initiates $7 | Strong Buy | Initiates | $7 | +278.38% | Jul 25, 2024 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-1.61
from -1.08
EPS Next Year
-1.90
from -1.61
Revenue Forecast
Revenue | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|---|
High | n/a | n/a | n/a | |||
Avg | n/a | n/a | n/a | |||
Low | n/a | n/a | n/a |
Revenue Growth
Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|---|
High | - | - | - | |||
Avg | - | - | - | |||
Low | - | - | - |
EPS Forecast
EPS | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|---|
High | -1.53 | -1.63 | -1.89 | |||
Avg | -1.61 | -1.90 | -1.98 | |||
Low | -1.67 | -2.10 | -2.05 |
EPS Growth
EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|---|
High | - | - | - | |||
Avg | - | - | - | |||
Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.